G01N 2800/28
Neurological disorders
G01N2800/28 (Neurological disorders) appears on 2,494 US grants and 5,249 published applications in this corpus.
Search patents in G01N- Granted patents
- 2,494
- Published applications
- 5,249
- Assignees
- 2,030
- Inventors
- 8,823
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 18 | 0 |
| 1994 | 6 | 0 |
| 1995 | 11 | 0 |
| 1996 | 11 | 0 |
| 1997 | 16 | 0 |
| 1998 | 32 | 0 |
| 1999 | 29 | 0 |
| 2000 | 28 | 0 |
| 2001 | 42 | 11 |
| 2002 | 32 | 84 |
| 2003 | 24 | 101 |
| 2004 | 36 | 104 |
| 2005 | 36 | 148 |
| 2006 | 53 | 176 |
| 2007 | 50 | 140 |
| 2008 | 42 | 156 |
| 2009 | 50 | 193 |
| 2010 | 79 | 221 |
| 2011 | 78 | 221 |
| 2012 | 76 | 198 |
| 2013 | 102 | 223 |
| 2014 | 101 | 249 |
| 2015 | 105 | 260 |
| 2016 | 114 | 276 |
| 2017 | 165 | 271 |
| 2018 | 146 | 283 |
| 2019 | 160 | 259 |
| 2020 | 166 | 248 |
| 2021 | 134 | 285 |
| 2022 | 122 | 271 |
| 2023 | 87 | 224 |
| 2024 | 111 | 249 |
| 2025 | 123 | 227 |
| 2026 | 88 | 171 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- G01N 2800/2814DementiaIndexing code1,264
- G01N 2800/2835Movement disordersIndexing code386
- G01N 2800/285Demyelinating diseasesIndexing code273
- G01N 2800/2871Cerebrovascular disordersIndexing code179
- G01N 2800/2842PainIndexing code83
- G01N 2800/2878Muscular dystrophyIndexing code65
- G01N 2800/2857Seizure disordersIndexing code50
- G01N 2800/2864Sleep disordersIndexing code36
All 9 subgroupsShow fewer
Recent patents
- ß-amyloid cyclic ribonucleic acid, polypeptide, and application thereof6 Oct 2026US 12,753,215 B2
- Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability29 Sep 2026US 12,746,255 B2Societe des Produits Nestle S. A.
- Tau-binding antibodies29 Sep 2026US 12,747,288 B2Ucb Biopharma Srl
- Methods for detecting phosphorylated alpha-synuclein22 Sep 2026US 12,742,789 B2Prothena Biosciences Limited
- FUS/TLS-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases15 Sep 2026US 12,735,745 B2The General Hospital Corporation
- Electrochemical biosensors, systems, and methods of use8 Oct 2026US 2026/0309671 A1
- Tau assay8 Oct 2026US 2026/0309720 A1
- Magnetic point-of-care systems and assays for determining gfap in biological samples8 Oct 2026US 2026/0309722 A1Abbott Laboratories
- Early detection and monitoring of neurodegenerative diseases using a multidisease diagnostic platform8 Oct 2026US 2026/0309723 A1Durin Life Sciences, Inc.
- Methods and compositions for diagnosing brain injury or neurodegeneration8 Oct 2026US 2026/0309724 A1Brainbox Solutions, Inc.
Most cited
By later US patents
- Polypeptide marker for Alzheimer's disease and its use for diagnosis318US 4,666,829 AUniversity of California · 1987
- Methods for the detection of soluble .beta.-amyloid peptide244US 5,593,846 AAthena Neurosciences, Inc. · 1997
- Antibodies to A4 amyloid peptide174US 5,231,000 AThe McLean Hospital Corporation · 1993
- Methods for monitoring cellular processing of .beta.-amyloid precursor protein167US 5,441,870 AAthena Neurosciences, Inc. · 1995
- Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production152US 5,766,846 AAthena Neurosciences, Inc. · 1998